Current Oncolytic Virus Approaches

Oncolytic viruses are highly immunogenic, but the dominance of anti-virus immune response triggered by standard oncolytic viruses may compromise the induction of tumor-targeted immune attack. Oncolysis releases tumor epitopes and may trigger the immune response which is unique to patient-specific neoantigens. In the reported clinical trials, however, tumor-specific immune response has been demonstrated only in some cancer patients while the induction of anti-virus immunity has been reported systematically in nearly all cancer patients treated with various different oncolytic viruses, including adenovirus.